Market Dynamics:

Rising incidence of congenital hyperinsulinism is a major factor driving the growth of this market. According to recent studies, the estimated annual incidence of CHI is 1 in 50,000 live births. Furthermore, improved diagnostic methods such as genetic testing and positron emission tomography (PET) scans have allowed early diagnosis and timely treatment of CHI, fueling market growth. The increasing research and funding for development of novel treatment options is also positively impacting the market. For instance, companies such as Zealand Pharma and Rezolute are developing next-generation therapies that specifically target the mechanisms leading to excessive insulin secretion in CHI. However, limited understanding of the disease pathophysiology and lack of definitive treatments present significant challenges to market players.

Key Takeaways

The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth.

For More Insights, Read: https://newsinsights123.blogspot.com/2023/12/the-global-congenital-hyperinsulinism.html